AryoGen Pharmed
AryoGen Pharmed is an Iranian biopharmaceutical manufacturer that develops and sells biosimilar monoclonal antibodies and recombinant proteins (Rituximab, Trastuzumab, Bevacizumab, Etanercept, Denosumab, Vedolizumab, Tocilizumab, Factor VIIa/VIII) for oncology, autoimmune, bone, and hemophilia indications in Iran, operating as a subsidiary of the SinaGen / Cinnagen Pharmaceutical Group.
- Company typePrivate
- Founded2009
- HeadquartersTehran, Iran
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What AryoGen Pharmed does
AryoGen Pharmed (آریوژن فارمد) is an Iranian biopharmaceutical company founded in 2009 that develops, manufactures, and commercializes biosimilar monoclonal antibodies and recombinant proteins. It is headquartered and produces at a single site in Garmdareh, Karaj County, Alborz Province, and operates as a core subsidiary within the SinaGen / Cinnagen Pharmaceutical Group, alongside sister companies Arako, Nano Alvand, and OrchidPharmed under Cinnagen as parent. The company employs 251-500 people and is led by CEO Mohammad Saffarioun.
AryoGen's technology platform is built on recombinant DNA expression using two mammalian cell systems — Chinese Hamster Ovary (CHO) cells and Baby Hamster Kidney (BHK) cells — maintained under cell bank regulations and stored in liquid nitrogen at -185°C, with downstream purification performed via chromatography methods. Its marketed portfolio comprises nine biosimilars targeting oncology (Rituximab/Zytux, Trastuzumab/Aryotrust, Bevacizumab/Stivant), inflammatory and autoimmune disease (Etanercept/Altebrel, Vedolizumab/Vedaryo, Tocilizumab/Temziva for COVID-19 cytokine release syndrome), bone disorders (Denosumab/Arylia), and hemophilia (rFVIIa/Aryoseven and rFVIII-Fc/Coageight).
Commercially, AryoGen distributes its products through conventional healthcare channels — hospitals, clinics, and pharmacies across Iran — within a country where pharmaceutical pricing is government-regulated. The group positions domestic biosimilar manufacturing as a foreign-currency-saving strategic asset for the Iranian healthcare system, and the company maintains a business development / export page on its website indicating intent to extend beyond the domestic single-country footprint.
AryoGen Pharmed firmographics
Firmographics- Name
- AryoGen Pharmed
- Legal name
- AryoGen Pharmed
- Website
- https://aryogen.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- AryoGen Pharmed is an Iranian biopharmaceutical manufacturer that develops and sells biosimilar monoclonal antibodies and recombinant proteins (Rituximab, Trastuzumab, Bevacizumab, Etanercept, Denosumab, Vedolizumab, Tocilizumab, Factor VIIa/VIII) for oncology, autoimmune, bone, and hemophilia indications in Iran, operating as a subsidiary of the SinaGen / Cinnagen Pharmaceutical Group.
- Ownership category
- akta.pro rank
AryoGen Pharmed industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)
- akta.pro secondary industries
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
Keywords
Where AryoGen Pharmed is headquartered
LocationHeadquarters
- HQ city
- Tehran
- HQ country
- Iran
- HQ region
- Middle East
Offices1 record
Markets served
AryoGen Pharmed business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- Biopharmaceutical Product Sales: AryoGen Pharmed generates revenue through the development, manufacturing, and sale of biologic pharmaceutical products including monoclonal antibodies and recombinant proteins for treatment of cancer, osteoporosis, hemophilia, and inflammatory diseases
Distribution channels1 record
Marketing channels4 records
AryoGen Pharmed product offering
Product offeringCore offering
AryoGen Pharmed manufactures biosimilar and innovative biologic pharmaceuticals, including monoclonal antibodies and recombinant proteins, for the treatment of cancer, autoimmune diseases, osteoporosis, hemophilia, and inflammatory conditions. Production relies on recombinant DNA technology expressed in Chinese Hamster Ovary (CHO) and Baby Hamster Kidney (BHK) cell systems, with purification performed via chromatography methods under regulated cell banking and quality control.
Product overview
AryoGen Pharmed is a biopharmaceutical company specializing in the development and manufacturing of recombinant biologic medicines. The company operates as part of the Sinagen Group pharmaceutical family and produces a portfolio of monoclonal antibody biosimilars and coagulation factor products using Chinese Hamster Ovary (CHO) and BHK cell expression systems. The product portfolio includes: Aryoseven (Recombinant Factor VIIa), Altebrel (Etanercept), Zytux (Rituximab), Aryotrust (Trastuzumab), Stivant (Bevacizumab), Temziva (Tocilizumab), Arylia (Denosumab), Vedaryo (Vedolizumab), and Coageight (Efmoroctocog alfa). These products target therapeutic areas including oncology, autoimmune diseases, bone disorders, and hemophilia, distributed across Iranian and export markets.
Differentiator
Problem solved
Functional benefit
Brands
- Aryoseven: Recombinant factor VII product produced using BHK cells (baby hamster kidney cells)
- Altebrel
- Zytux
- Aryotrust
- Stivant
- Temziva
- Arylia
- Coageight
Products and services
- Aryoseven (Recombinant Coagulation Factor VIIa / Eptacog alfa) Recombinant Factor VIIa (Eptacog alfa) produced using BHK (Baby Hamster Kidney) cells stored in liquid nitrogen at -185°C under cell bank regulations; used for treatment of bleeding episodes in patients with hemophilia and related coagulation disorders.
- Altebrel (Etanercept) Etanercept biosimilar produced through pre-purification and purification steps using chromatography methods for final formulation; used for treatment of inflammatory conditions including rheumatoid arthritis and related autoimmune diseases.
- Zytux (Rituximab) Rituximab biosimilar — a chimeric (murine-human) monoclonal antibody targeting the CD20 antigen on abnormal and malignant B lymphocytes, produced using recombinant DNA technology in Chinese Hamster Ovary (CHO) cells; used for treatment of B-cell lymphomas, leukemias, and autoimmune conditions.
- Aryotrust (Trastuzumab) Trastuzumab biosimilar produced using CHO (Chinese Hamster Ovary) cells as the manufacturing platform; used for treatment of HER2-positive breast cancer and other HER2-overexpressing malignancies.
- Stivant (Bevacizumab) Bevacizumab biosimilar — a recombinant monoclonal antibody that binds to Vascular Endothelial Growth Factor (VEGF) to inhibit tumor angiogenesis; used for treatment of metastatic colorectal cancer, glioblastoma, non-small cell lung cancer, advanced/metastatic kidney cancer, ovarian cancer, fallopian tube and primary peritoneal cancer, cervical cancer, and metastatic breast cancer. Available in 4 mL (100 mg) and 16 mL (400 mg) vials at 25 mg/mL concentration.
- Temziva (Tocilizumab) Tocilizumab biosimilar used for treatment of Cytokine Release Syndrome (CRS) as the main cause of deterioration in adult patients confirmed with COVID-19; also used for rheumatoid arthritis and other inflammatory conditions.
- Arylia (Denosumab) Denosumab biosimilar — a monoclonal antibody (IgG2) that specifically targets the RANKL protein, blocking bone resorption by inhibiting osteoclast formation, function, and survival; used for treatment of osteoporosis in postmenopausal women and men at high risk of bone fracture, and other bone-loss conditions.
- Vedaryo (Vedolizumab) Vedolizumab biosimilar — an IgG1 monoclonal antibody targeting human α4β7 integrin, produced using recombinant DNA technology in CHO cells; blocks the integrin on white blood cells that drives inflammation in ulcerative colitis and Crohn's disease.
- Coageight (Efmoroctocog alfa — Recombinant Coagulation Factor VIII Fc Fusion Protein) Efmoroctocog alfa, a recombinant Coagulation Factor VIII Fc fusion protein effective in blood clotting, produced using recombinant DNA in CHO cells without human or animal-derived components; used for prevention and treatment of bleeding in patients with Hemophilia A across all age groups. Available in 500 IU and 2000 IU lyophilized powder vials with diluent.
Companies that use AryoGen Pharmed
Customer profileSegments1 record
Ideal customer profiles1 record
AryoGen Pharmed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
AryoGen Pharmed partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- SinaGen Pharmaceutical Group (گروه دارویی سیناژن)coreAryoGen Pharmed is a subsidiary company within the SinaGen Pharmaceutical Group, Iran's pharmaceutical conglomerate. The group comprises four subsidiary companies with SinaGen as the parent company, focusing on biologic and biosimilar pharmaceutical development and manufacturing.
- Arako (ارکو)minorSubsidiary of SinaGen Pharmaceutical Group, operates in the biotech/pharmaceutical sector
- NanoAlvand (نانو آلواند)minorNanotechnology pharmaceutical company within the SinaGen Group
- CinaGen (سیناژن)coreCore subsidiary and parent company of the SinaGen Pharmaceutical Group, focused on pharmaceutical development and manufacturing
- Orchid Pharmed (ارکید فارمد)minorSubsidiary company within the SinaGen pharmaceutical ecosystem
Recent moves6 records
Expansion highlights5 records
AryoGen Pharmed competitors and assessment
Company assessmentDirect peers
- Celltrion: South Korean biosimilar manufacturer specializing in mAb biosimilars (rituximab, trastuzumab, bevacizumab, infliximab) using mammalian cell culture; directly comparable to AryoGen in product mix, expression systems, and target therapeutic areas.
- Biocon Biologics: Indian biosimilar developer and manufacturer with a portfolio overlapping AryoGen's (trastuzumab, rituximab, bevacizumab, etanercept) targeting oncology and autoimmune indications in emerging markets.
- Samsung Bioepis: Joint venture between Samsung Biologics and Biogen producing biosimilars including etanercept, infliximab, adalimumab, trastuzumab, and bevacizumab; competes head-to-head with AryoGen in mAb biosimilars using CHO cell platforms.
- Dr. Reddy's Laboratories: Indian generics and biosimilars company with rituximab, bevacizumab, and other mAb biosimilars in development and emerging-market commercialization; comparable in geographic focus and product strategy.
- Intas Pharmaceuticals: Indian biopharmaceutical company marketing biosimilars such as rituximab, trastuzumab, and denosumab in India and emerging markets; directly comparable portfolio overlap with AryoGen's oncology and bone-disease assets.
- Hetero Biopharma: Indian biosimilar manufacturer producing rituximab, bevacizumab, denosumab and other mAbs using CHO cell technology; competes with AryoGen in cost-sensitive emerging market tenders.
Broad incumbents
- Amgen: Originator manufacturer of etanercept (Enbrel) and developer/manufacturer of multiple biosimilars (via Amgen-Allergan partnership) such as rituximab, trastuzumab, and bevacizumab biosimilars; serves as both reference product maker and direct biosimilar competitor.
Regional players
- CinnaGen (parent group): Parent company of AryoGen within the SinaGen group, also producing biotech/pharmaceutical products in Iran; provides direct intra-group comparison and shares commercial and distribution infrastructure with AryoGen.
- Arako Pharmaceutical Co. Iranian biotech subsidiary within the SinaGen group, also producing biologic products for the domestic Iranian market; comparable in geography, regulatory environment, and business model.
Emerging players
- Reliance Life Sciences: Indian biosimilar and plasma-product manufacturer with biosimilars in oncology (rituximab, trastuzumab) and recombinant proteins (factor VIII); comparable scale and product mix to AryoGen in emerging-market focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
AryoGen Pharmed social profiles
Digital presenceAryoGen Pharmed financial estimates
Financial estimateRevenue estimate
Valuation estimate
AryoGen Pharmed leadership team
Management profileNumber of profiles
Profiles1 record
AryoGen Pharmed funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AryoGen Pharmed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AryoGen Pharmed
What does AryoGen Pharmed do?
AryoGen Pharmed manufactures biosimilar and innovative biologic pharmaceuticals, including monoclonal antibodies and recombinant proteins, for the treatment of cancer, autoimmune diseases, osteoporosis, hemophilia, and inflammatory conditions. Production relies on recombinant DNA technology expressed in Chinese Hamster Ovary (CHO) and Baby Hamster Kidney (BHK) cell systems, with purification performed via chromatography methods under regulated cell banking and quality control.
When was AryoGen Pharmed founded?
AryoGen Pharmed was founded in 2009. It employs 251 to 500 people.
Where is AryoGen Pharmed based?
AryoGen Pharmed is headquartered in Tehran, Iran, in the Middle East region.
How does AryoGen Pharmed make money?
One revenue line is on record: biopharmaceutical Product Sales.
Who are AryoGen Pharmed's main competitors?
Direct peers on record are Celltrion, Biocon Biologics, Samsung Bioepis, Dr. Reddy's Laboratories, Intas Pharmaceuticals and Hetero Biopharma. Amgen is listed as a broad incumbent. Regional players are CinnaGen (parent group) and Arako Pharmaceutical Co.. Reliance Life Sciences is listed as an emerging player.
Does AryoGen Pharmed have an API?
No public API is recorded for AryoGen Pharmed.
What industry is AryoGen Pharmed in?
AryoGen Pharmed's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors), with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.